[go: up one dir, main page]

RU2018140988A - Способы и композиции для усиления противовоспалительных эффектов интерлейкина 10 - Google Patents

Способы и композиции для усиления противовоспалительных эффектов интерлейкина 10 Download PDF

Info

Publication number
RU2018140988A
RU2018140988A RU2018140988A RU2018140988A RU2018140988A RU 2018140988 A RU2018140988 A RU 2018140988A RU 2018140988 A RU2018140988 A RU 2018140988A RU 2018140988 A RU2018140988 A RU 2018140988A RU 2018140988 A RU2018140988 A RU 2018140988A
Authority
RU
Russia
Prior art keywords
vector
peptide
vectors
inflammation
interleukin
Prior art date
Application number
RU2018140988A
Other languages
English (en)
Other versions
RU2018140988A3 (ru
RU2731160C2 (ru
Inventor
Джон ФОРСЭЙЕТ
Рэймонд ЧАВЕС
Линда УОТКИНЗ
Питер ГРЭЙС
Original Assignee
Ксалюд Терапьютикс, Инк.
Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ксалюд Терапьютикс, Инк., Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт filed Critical Ксалюд Терапьютикс, Инк.
Publication of RU2018140988A publication Critical patent/RU2018140988A/ru
Publication of RU2018140988A3 publication Critical patent/RU2018140988A3/ru
Application granted granted Critical
Publication of RU2731160C2 publication Critical patent/RU2731160C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Claims (21)

1. Способ лечения воспаления у субъекта, включающий экспрессию с одного или нескольких бактериальных, вирусных, фаговых, космидных векторов или векторов на основе искусственной хромосомы пептида интерлейкина 10 (IL-10) и пептида рецептора интерлейкина 10 типа 1 (IL-10R1) в антигенпредставляющих клетках у субъекта.
2. Способ по п.1, где пептид IL-10, экспрессированный в антигенпредставляющих клетках, содержит мутацию в шарнирной области пептида IL-10.
3. Способ по п.2, где пептид IL-10 содержит мутацию, где фенилаланин в положении 129 последовательности IL-10 дикого типа заменен на серин, треонин, аланин или цистеин.
4. Способ по п.3, где фенилаланин в положении 129 последовательности дикого типа заменен на серин.
5. Способ по п.1, где IL-10 и IL-10R1 экспрессируются с одного вектора.
6. Способ по п.5, где вектор представляет собой вирусный вектор.
7. Способ по п.6, где вирусный вектор представляет собой аденоассоциированный вирусный вектор.
8. Способ по п.6, где вирусный вектор представляет собой лентивирусный вектор.
9. Способ по п.5, где кодирующие последовательности IL-10 и IL-10R1 транскрибируются в форме одной мРНК.
10. Способ по п.9, где вектор дополнительно содержит кодирующую последовательность для внутреннего участка связывания рибосомы между кодирующими последовательностями IL-10 и IL-10R1.
11. Способ по п.9, где вектор дополнительно содержит кодирующую последовательность для саморасщепляющегося пептида 2a между кодирующими последовательностями IL-10 и IL-10R1.
12. Способ по п.1, где воспаление вызвано нейропатической или хронической болью, и один или несколько векторов доставляют посредством интратекальной инъекции.
13. Способ по п.1, где воспаление вызвано MS, и один или несколько векторов доставляют посредством интратекальной инъекции.
14. Способ по п.1, где воспаление вызвано аутоиммунным заболеванием, и один или несколько векторов доставляют посредством интратекальной инъекции.
15. Способ по п.1, где воспаление локализовано в суставе, и один или несколько векторов доставляют посредством интраартикулярной инъекции.
16. Способ по п.1, где воспаление представляет собой нейровоспаление.
17. Способ по п.1, где антигенпредставляющие клетки выбраны из группы из монобластов, моноцитов, астроцитов, олигодендроцитов, микроглии, макрофагов, В-клеток, дендритных клеток, пенистых клеток, лимфобластов и В-лимфоцитов.
18. Способ по п.17, где антигенпредставляющие клетки отбирают у субъекта, подлежащего лечению, трансдуцируют одним или несколькими векторами in vitro и вводят обратно субъекту.
19. Способ по п.17, где антигенпредставляющие клетки стабильно трансформируют одним или несколькими векторами и поддерживают в культуре.
20. Одиночный вирусный или бактериальный экспрессирующий вектор, содержащий кодирующие области для интерлейкина 10 (IL-10) и рецептора интерлейкина 10 типа 1 (IL-10R1).
21. Одиночный экспрессирующий вектор по п.20, где вектор представляет собой вирусный вектор, содержащий один промотор, управляющий транскрипцией пептидов IL-10 и IL-10R1, и дополнительно содержит саморасщепляющийся пептид 2a, расположенный между кодирующей областью пептида IL-10 и кодирующей областью пептида IL-10R1.
RU2018140988A 2016-04-22 2017-04-21 Способы и композиции для усиления противовоспалительных эффектов интерлейкина 10 RU2731160C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326082P 2016-04-22 2016-04-22
US62/326,082 2016-04-22
PCT/US2017/028755 WO2017184933A1 (en) 2016-04-22 2017-04-21 Methods and compositions to enhance the anti-inflammatory effects of interleukin 10

Publications (3)

Publication Number Publication Date
RU2018140988A true RU2018140988A (ru) 2020-05-22
RU2018140988A3 RU2018140988A3 (ru) 2020-05-25
RU2731160C2 RU2731160C2 (ru) 2020-08-31

Family

ID=60116475

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018140988A RU2731160C2 (ru) 2016-04-22 2017-04-21 Способы и композиции для усиления противовоспалительных эффектов интерлейкина 10

Country Status (11)

Country Link
US (2) US20190112354A1 (ru)
EP (1) EP3445849B1 (ru)
JP (2) JP7163189B2 (ru)
KR (1) KR102430455B1 (ru)
CN (1) CN109477085B (ru)
AU (1) AU2017252327B2 (ru)
CA (1) CA3019846A1 (ru)
DK (1) DK3445849T3 (ru)
IL (1) IL262195B2 (ru)
RU (1) RU2731160C2 (ru)
WO (1) WO2017184933A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3369435B1 (en) 2013-07-18 2019-09-04 Xalud Therapeutics, Inc. Composition for the treatment of inflammatory joint disease
WO2019226519A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
US20220378025A1 (en) * 2019-11-11 2022-12-01 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
KR102466921B1 (ko) * 2021-06-29 2022-11-14 주식회사 오에이티씨 인터루킨-4를 암호화하는 유전자를 포함하는 신경병증성 통증의 예방 또는 치료용 약학적 조성물
WO2023114958A1 (en) * 2021-12-16 2023-06-22 Xalud Therapeutics, Inc. Dosing regimen for il-10 encoding expression construct

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716804A (en) * 1995-04-19 1998-02-10 Schering Corporation Mammalian interleukin-10 (IL-10) super-activating receptors; and variants
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2006130580A2 (en) * 2005-05-31 2006-12-07 Avigen, Inc. Mutant il-10
CN107519499A (zh) * 2010-03-23 2017-12-29 英特瑞克斯顿股份有限公司 条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用
US9315825B2 (en) * 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
WO2013103966A1 (en) 2012-01-06 2013-07-11 The Regents Of The University Of Colorado, A Body Corporate Methods for the treatment of multiple sclerosis and other demyelinating disorders
EP3369435B1 (en) * 2013-07-18 2019-09-04 Xalud Therapeutics, Inc. Composition for the treatment of inflammatory joint disease

Also Published As

Publication number Publication date
US20190112354A1 (en) 2019-04-18
US20240352089A1 (en) 2024-10-24
JP2022169585A (ja) 2022-11-09
CA3019846A1 (en) 2017-10-26
KR102430455B1 (ko) 2022-08-05
IL262195B2 (en) 2023-09-01
RU2018140988A3 (ru) 2020-05-25
EP3445849B1 (en) 2024-06-05
CN109477085A (zh) 2019-03-15
RU2731160C2 (ru) 2020-08-31
DK3445849T3 (da) 2024-08-05
JP7163189B2 (ja) 2022-10-31
KR20190021211A (ko) 2019-03-05
IL262195B1 (en) 2023-05-01
EP3445849A4 (en) 2019-09-25
IL262195A (en) 2018-11-29
JP2019518003A (ja) 2019-06-27
EP3445849A1 (en) 2019-02-27
AU2017252327B2 (en) 2023-05-25
WO2017184933A1 (en) 2017-10-26
AU2017252327A1 (en) 2018-11-15
CN109477085B (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
RU2018140988A (ru) Способы и композиции для усиления противовоспалительных эффектов интерлейкина 10
JP2019518003A5 (ru)
CN113454110B (zh) Ny-eso-1 t细胞受体和其使用方法
JP6893945B2 (ja) Ｔａｌｅｎに基づく遺伝子修正
Chong et al. IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses
Zhang et al. GDF15 regulates Malat-1 circular RNA and inactivates NFκB signaling leading to immune tolerogenic DCs for preventing alloimmune rejection in heart transplantation
Doorduijn et al. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors
JP6561372B2 (ja) 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター
JP5980508B2 (ja) 自己免疫障害に対する処置方法
Zhu et al. High-avidity T cells are preferentially tolerized in the tumor microenvironment
Abraham et al. IL-10 exacerbates xenogeneic GVHD by inducing massive human T cell expansion
Etxeberria et al. Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms
Schäffler et al. The human apM-1, an adipocyte-specific gene linked to the family of TNF's and to genes expressed in activated T cells, is mapped to chromosome 1q21. 3-q23, a susceptibility locus identified for familial combined hyperlipidaemia (FCH)
WO2016133779A1 (en) A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
US9629897B2 (en) Methods of producing and using regulatory B-cells
US20210380683A1 (en) Modulation of irf-4 and uses thereof
CN118240767A (zh) 作为减少或预防转移、治疗自身免疫和炎性病症以及重新平衡免疫环境和失调的小生境的平台的基因修饰的hspc及间充质细胞
Mondanelli et al. Islet antigen-pulsed dendritic cells expressing ectopic IL-35Ig protect nonobese diabetic mice from autoimmune diabetes
WO2019071029A1 (en) PREVENTION AND TREATMENT OF GVHD AND OTHER AUTOIMMUNE DISEASES
ES2972793T3 (es) Células diseñadas para inducir tolerancia
Cap et al. Lymphatic PD-L1 expression restricts tumor-specific CD8+ T cell responses
CA3137808A1 (en) Cd5 specific t cell receptor cell or gene therapy
Horn et al. Gene therapy in the transplantation of allogeneic organs and stem cells
JP2015136293A (ja) 腎細胞癌の予防又は治療に好適なペプチド、核酸分子、及びベクター、並びにそれらの利用
Zhang Leading to Immune Tolerogenic DCs for Preventing Alloimmune Rejection